Tratamiento de infecciones graves por Acinetobacter baumannii
Tài liệu tham khảo
OMS. La OMS publica la lista de las bacterias para las que se necesitan urgentemente nuevos antibióticos. [consultado Ago 2022]. Disponible en: https://www.who.int/es/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed
2022, Global burden of bacterial antimicrobial resistance in 2019: a systematic análisis, Lancet., 399, 629, 10.1016/S0140-6736(21)02724-0
Moffatt, 2019, Mechanisms of Polymyxin Resistance, Adv Exp Med Biol., 1145, 55, 10.1007/978-3-030-16373-0_5
Vázquez-López, 2020, Acinetobacter baumannii resistance: A real challenge for clinicians, Antibiotics., 9, 205, 10.3390/antibiotics9040205
Mohd Sazlly Lim, 2019, The global prevalence of multidrug-resistance among Acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality: A systematic review and meta-analysis, J Infect., 79, 593, 10.1016/j.jinf.2019.09.012
Amaya-Villar, 2019, How should we treat acinetobacter pneumonia?, Curr Opin Crit Care., 25, 465, 10.1097/MCC.0000000000000649
Nguyen, 2021, Carbapenem resistance in Acinetobacter baumannii, and their importance in hospital-acquired infections: a scientific review, J Applied Microbiology., 131, 2715, 10.1111/jam.15130
Drinka, 2009, Does Biofilm Formation Play a Role in Ventilator-Associated Tracheobronchitis?, Chest., 136, 1190, 10.1378/chest.09-0465
Nseir, 2014, Impact of appropriate antimicrobial treatment on transition from ventilator-associated tracheobronchitis to ventilator-associated pneumonia, Critical Care., 18, R129, 10.1186/cc13940
Craven, 2014, Antibiotic treatment of ventilator-associated tracheobronchitis: to treat or not to treat?, Curr Opin Crit Care., 20, 532, 10.1097/MCC.0000000000000130
Valachis, 2015, The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: a systematic review and metaanalysis, Crit Care Med., 43, 527, 10.1097/CCM.0000000000000771
Kollef, 2017, A randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of Gram-negative ventilator-associated pneumonia: IASIS trial, Chest., 151, 1239, 10.1016/j.chest.2016.11.026
Lee, 2012, Impact of Appropriate Antimicrobial Therapy on Mortality Associated With Acinetobacter baumannii Bacteremia: Relation to Severity of Infection, Clin Infect Dis., 55, 209, 10.1093/cid/cis385
Garnacho-Montero, 2019, Managing Acinetobacter baumannii infections, Curr Opin Infect Dis., 32, 69, 10.1097/QCO.0000000000000518
European Committee on Antimicrobial Susceptibility Testing. Colistin Breakpoints – guidance document 2021. [consultado Ago 2022]. Disponible en: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Guidance_documents/Colistin_guidance_2021.pdf.
Tsuji, 2019, Pharmacotherapy., 39, 10, 10.1002/phar.2209
Sandri, 2013, Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens, Clin Infect Dis., 57, 524, 10.1093/cid/cit334
Owen, 2007, In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates, J Antimicrob Chemother., 59, 473, 10.1093/jac/dkl512
Poudyal, 2008, In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae, J Antimicrob Chemother., 62, 1311, 10.1093/jac/dkn425
Bergen, 2010, Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model, Antimicrob Agents Chemother., 54, 3783, 10.1128/AAC.00903-09
Tran, 2016, Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii, J Antibiot (Tokyo)., 69, 415, 10.1038/ja.2015.127
Abdul Rahim, 2015, Synergistic killing of NDM-producing MDR Klebsiella pneumoniae by two ‘old’ antibiotics—polymyxin B and chloramphenicol, J Antimicrob Chemother., 70, 2589, 10.1093/jac/dkv135
Tam, 2005, Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa, Antimicrob Agents Chemother., 49, 3624, 10.1128/AAC.49.9.3624-3630.2005
Li, 2006, Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii, Antimicrob Agents Chemother., 50, 2946, 10.1128/AAC.00103-06
Meletis, 2011, Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae, J Antimicrob Chemother., 66, 946, 10.1093/jac/dkr007
Bergen, 2011, Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula, Antimicrob Agents Chemother., 55, 5134, 10.1128/AAC.05028-11
Kubin, 2012, Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy, J Infect., 65, 80, 10.1016/j.jinf.2012.01.015
Akajagbor, 2013, Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center, Clin Infect Dis., 57, 1300, 10.1093/cid/cit453
Suzuki, 2013, Megalin contributes to kidney accumulation and nephrotoxicity of colistin, Antimicrob Agents Chemother., 57, 6319, 10.1128/AAC.00254-13
Lu, 2016, Human oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins, J Antimicrob Chemother., 71, 403, 10.1093/jac/dkv340
Azad, 2013, Polymyxin B induces apoptosis in kidney proximal tubular cells, Antimicrob Agents Chemother., 57, 4329, 10.1128/AAC.02587-12
Eadon, 2013, Cell cycle arrest in a model of colistin nephrotoxicity, Physiol Genomics., 45, 877, 10.1152/physiolgenomics.00076.2013
Vardakas, 2018, Intravenous plus inhaled versus intravenous colistin monotherapy for lower respiratory tract infections: A systematic review and meta-analysis, J Infect., 76, 321, 10.1016/j.jinf.2018.02.002
U.S. Food & Drug Administration (FDA). FDA Drug Safety Communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. [consultado Ago 2022]. Disponible en: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-increased-risk-death-tygacil-tigecycline-compared-other-antibiotics.
Ramirez, 2013, Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia, Antimicrob Agents Chemother, 57, 1756, 10.1128/AAC.01232-12
Jaruratanasirikul, 2013, Pharmacodynamics modeling to optimize dosage regimens of sulbactam, Antimicrob Agents Chemother., 57, 3441, 10.1128/AAC.00342-13
Tamma, 2022, Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections, Clin Infect Dis., 74, 2089, 10.1093/cid/ciab1013
López-Cortés, 2014, Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort, J Antimicrob Chemother., 69, 3119, 10.1093/jac/dku233
Aydemir, 2013, Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia, Epidemiol Infect., 141, 1214, 10.1017/S095026881200194X
Park, 2019, Colistin monotherapy versus colistin/rifampicin combination therapy in pneumonia caused by colistin resistant Acinetobacter baumannii: a randomised controlled trial, J Glob Antimicrob Resist., 17, 66, 10.1016/j.jgar.2018.11.016
Makris, 2018, Colistin versus colistin combined with ampicillin sulbactam for multiresistant Acinetobacter baumannii ventilator associated pneumonia treatment: an open-label prospective study, Indian J Crit Care Med., 22, 67, 10.4103/ijccm.IJCCM_302_17
Sirijatuphat, 2014, Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections, Antimicrob Agents Chemother., 58, 5598, 10.1128/AAC.02435-13
Tamma, 2022, Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase–Producing Enterobacterales Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections, Clin Infect Dis., 74, 2089, 10.1093/cid/ciab1013
Paul, 2022, European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine), Clin Microbiol Infect., 28, 521, 10.1016/j.cmi.2021.11.025
De Waele, 2018, Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multidrug resistance, Intensive Care Med., 44, 189, 10.1007/s00134-017-5036-1
Anthony, 2021, The Gut Microbiome as a Reservoir for Antimicrobial Resistance, J Infect Dis., 223, S209, 10.1093/infdis/jiaa497
Royer, 2018, Shorter versus longer courses of antibiotics for infection in hospitalized patients: a systematic review and meta-analysis, J Hosp Med., 13, 336, 10.12788/jhm.2905
De Waele, 2018, Optimal duration of antibiotic treatment in Gram-negative infections, Curr Opin Infect Dis., 31, 606, 10.1097/QCO.0000000000000491
Tansarli, 2019, Systematic Review and Meta-analysis of Antibiotic Treatment Duration for Bacteremia Due to Enterobacteriaceae, Antimicrob Agents Chemother., 63, e02495, 10.1128/AAC.02495-18
Chastre, 2003, Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial, JAMA., 290, 2588, 10.1001/jama.290.19.2588
Kalil, 2016, Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society, Clin Infect Dis., 63, 575, 10.1093/cid/ciw504
Evans, 2021, Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021, Crit Care Med., 49, e1063, 10.1097/CCM.0000000000005337
Morrissey, 2020, In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017, Antimicrob Agents Chemother., 64, e01699
Scott, 2022, Efficacy of Eravacycline Versus Best Previously Available Therapy for Adults With Pneumonia Due to Difficult-to-Treat Resistant (DTR) Acinetobacter baumannii, Ann Pharmacother., 10.1177/10600280221085551
McLeod, 2020, In Vitro Activity of Sulbactam-Durlobactam against Acinetobacter baumannii-calcoaceticus Complex Isolates Collected Globally in 2016 and 2017, Antimicrob Agents Chemother., 64, e02534, 10.1128/AAC.02534-19